人性化护理在晚期结直肠癌患者化疗中的应用效果
2015-10-21慕楠
慕楠



[摘要] 目的 观察人性化护理干预在晚期结直肠癌患者化疗中的应用效果。 方法 选择2013年2月~2015年2月我院确诊为晚期结直肠癌的86例患者,按照入院先后顺序将其分为对照组(n=41)和观察组(n=45)。两组患者均根据晚期结直肠癌指南给予合理正规的化疗方案,对照组给予常规护理,观察组给予人性化护理,比较两组患者的效果差异性。 结果 观察组的总满意度显著高于对照组,差异有统计学意义(P<0.01)。干预后,两组的SAS、SDS 、VAS评分较干预前均降低(P<0.05),且观察组降低更明显,两组差异有统计学意义(P<0.05)。 结论 人性化护理干预可以显著改善晚期结直肠癌患者化疗中的不良情绪及疼痛,值得推广。
[关键词] 人性化护理;晚期结直肠癌;化疗
[中图分类号] R473.73 [文献标识码] A [文章编号] 1674-4721(2015)09(a)-0195-03
[Abstract] Objective To explore the clinical efficacy of individual human nursing in chemotherapy for patients with advanced colorectal cancer. Methods 86 patients with advanced colorectal cancer in our hospital from February 2013 to February 2015 were selected.They were divided into control group (n=41) and observation group (n=45) according to the order of admission. Two groups were adopted routine chemotherapy on the basis of the advanced colorectal cancer guidelines.The control group was given conventional care,while the observation group was given individual human nursing.The clinical efficacy was compared between two groups. Results The total satisfaction rate in observation group was significantly higher than that of control group,and the difference was statistically significant(P<0.01).The score of SAS,SDS and VAS in two groups were improved after the intervention(P<0.05),and the observation group improved more,the difference was statistically significant(P<0.05). Conclusion Individual human nursing is worth popularizing in clinical for improving emotion and pain in chemotherapy patients with advanced colorectal cancer.
[Key words] Individual human nursing;Advanced colorectal cancer;Chemotherapy
结直肠癌是临床中较常见的消化道肿瘤,居我国所有癌症发病率第4位。随着人们生活方式和饮食结构的改变以及多基因调控的深入研究,发现结直肠癌的发病机制与长期慢性炎症刺激密切相关,其发病率逐年增加,且有年轻化的趋势。直肠癌的早期症状不典型,一般出现大便形状改变、腹部疼痛时往往已经进展到晚期,伴随其他脏器的转移,丧失早期手术切除机会,预后较差。对于晚期癌症患者,化疗是必要的,但是化疗的不良反应对患者身心健康均是巨大的挑战[1]。本研究采用人性化护理干预对晚期结直肠癌患者进行护理,效果显著。
1 资料与方法
1.1 一般资料
选择2013年2月~2015年2月我院确诊为晚期结直肠癌的86例患者,所有患者均经肠镜下组织活检,病理诊断证实。入选标准:符合晚期结直肠癌诊断标准,均为首次治疗。排除结直肠继发肿瘤,合并其他脏器原发肿瘤,不能耐受常规化疗药物,严重肝肾功能障碍,严重感染、贫血无法纠正,预计生存期<12个月及拒绝本研究的患者。……
